Kalantari, F.; Mirshahvalad, S.A.; Hoellwerth, M.; Schweighofer-Zwink, G.; Huber-Schönauer, U.; Hitzl, W.; Rendl, G.; Koelblinger, P.; Pirich, C.; Beheshti, M.
Prognostic Value of Baseline 18F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients. Cancers 2024, 16, 127.
https://doi.org/10.3390/cancers16010127
AMA Style
Kalantari F, Mirshahvalad SA, Hoellwerth M, Schweighofer-Zwink G, Huber-Schönauer U, Hitzl W, Rendl G, Koelblinger P, Pirich C, Beheshti M.
Prognostic Value of Baseline 18F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients. Cancers. 2024; 16(1):127.
https://doi.org/10.3390/cancers16010127
Chicago/Turabian Style
Kalantari, Forough, Seyed Ali Mirshahvalad, Magdalena Hoellwerth, Gregor Schweighofer-Zwink, Ursula Huber-Schönauer, Wolfgang Hitzl, Gundula Rendl, Peter Koelblinger, Christian Pirich, and Mohsen Beheshti.
2024. "Prognostic Value of Baseline 18F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients" Cancers 16, no. 1: 127.
https://doi.org/10.3390/cancers16010127
APA Style
Kalantari, F., Mirshahvalad, S. A., Hoellwerth, M., Schweighofer-Zwink, G., Huber-Schönauer, U., Hitzl, W., Rendl, G., Koelblinger, P., Pirich, C., & Beheshti, M.
(2024). Prognostic Value of Baseline 18F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients. Cancers, 16(1), 127.
https://doi.org/10.3390/cancers16010127
